This HTML5 document contains 136 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n24http://or.dbpedia.org/resource/
n20https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
n14http://dbpedia.org/resource/List_of_drugs:
dbpedia-ruhttp://ru.dbpedia.org/resource/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
dbpedia-cshttp://cs.dbpedia.org/resource/
n9https://druginfo.nlm.nih.gov/drugportal/name/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
dbpedia-arhttp://ar.dbpedia.org/resource/
owlhttp://www.w3.org/2002/07/owl#
dbpedia-frhttp://fr.dbpedia.org/resource/
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
goldhttp://purl.org/linguistics/gold/
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Psoriasis
dbo:wikiPageWikiLink
dbr:Brodalumab
Subject Item
dbr:Bausch_Health
dbo:wikiPageWikiLink
dbr:Brodalumab
Subject Item
dbr:Institute_for_Clinical_and_Economic_Review
dbo:wikiPageWikiLink
dbr:Brodalumab
Subject Item
dbr:Interleukin-17_receptor
dbo:wikiPageWikiLink
dbr:Brodalumab
Subject Item
dbr:Kyntheum
dbo:wikiPageWikiLink
dbr:Brodalumab
dbo:wikiPageRedirects
dbr:Brodalumab
Subject Item
dbr:Siliq
dbo:wikiPageWikiLink
dbr:Brodalumab
dbo:wikiPageRedirects
dbr:Brodalumab
Subject Item
dbr:Monoclonal_antibody_therapy
dbo:wikiPageWikiLink
dbr:Brodalumab
Subject Item
dbr:Brodalumab
rdf:type
n3:ChemicalObject yago:Protein114728724 yago:OrganicCompound114727670 yago:Matter100020827 yago:Macromolecule114944888 yago:MonoclonalAntibody115029781 yago:Compound114818238 yago:Part113809207 yago:Unit109465459 yago:Chemical114806838 yago:Abstraction100002137 yago:WikicatMonoclonalAntibodies yago:Relation100031921 dbo:Drug wikidata:Q8386 yago:PhysicalEntity100001930 yago:Material114580897 yago:Antibody115027189 yago:Molecule114682133 dbo:ChemicalSubstance owl:Thing dbo:MonoclonalAntibody yago:Thing100002452 yago:Substance100019613
rdfs:label
برودالوماب Brodalumab Brodalumab Brodalumab Бродалумаб
rdfs:comment
Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases. In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments. برودالوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج أمراض التهابية طورته آمجن. Brodalumab (v USA pod názvem Siliq, v Evropě Kyntheum) je lidská monoklonální protilátka určená k léčbě zánětlivých onemocnění.V únoru 2017 byl Brodalumab schválen FDA pro léčbu středně těžké až těžké (lupénky) u lidí, jejichž předchozí léčba selhala. Le brodalumab est un anticorps monoclonal ciblant le récepteur A de l'interleukine 17 (IL-17RA). Il agit comme antagoniste des récepteurs à l'IL-17 comparativement aux autres inhibiteurs de l'IL-17, qui eux vont agir sur l'IL-17 et non sur son récepteur en la neutralisant. Il est aujourd'hui approuvé dans différentes juridictions dans le traitement du psoriasis modéré à sévère. Бродалумаб (brodalumab) — лекарственный препарат, моноклональное антитело. Одобрен для применения: США (февраль 2017 года).
dcterms:subject
dbc:Amgen
dbo:wikiPageID
33023911
dbo:wikiPageRevisionID
1124010770
dbo:wikiPageWikiLink
dbr:LEO_Pharma dbr:Ustekinumab dbr:Interleukin_17_receptor_A dbr:Biologics_license_application dbr:Interleukin-17_receptor dbr:Kyowa_Hakko_Kirin dbr:Monoclonal_antibody dbr:Valeant_Pharmaceuticals dbr:Plaque_psoriasis dbr:Primary_endpoint dbr:Ixekizumab dbr:FDA dbc:Amgen dbr:AstraZeneca dbr:Amgen dbr:Interleukin_17
dbo:wikiPageExternalLink
n9:brodalumab
owl:sameAs
wikidata:Q4972934 yago-res:Brodalumab dbpedia-cs:Brodalumab dbpedia-ar:برودالوماب dbpedia-fr:Brodalumab n20:4caiE n24:ବ୍ରୋଡାଲୁମାବ freebase:m.0h561_2 dbpedia-ru:Бродалумаб
dbp:wikiPageUsesTemplate
dbt:Interleukin_receptor_modulators dbt:Portal_bar dbt:Reflist dbt:Monoclonals_for_immune_system dbt:Drugbankcite dbt:Keggcite dbt:Drugbox dbt:Antineoplastic-drug-stub dbt:Redirect dbt:Chemspidercite dbt:Cascite dbt:Monoclonal-antibody-stub dbt:Fdacite dbt:Cite_web
dbp:atcSuffix
AC12
dbp:atcPrefix
L04
dbp:c
6372
dbp:casNumber
1174395
dbp:chemspiderid
none
dbp:drugbank
DB11776
dbp:h
9840
dbp:kegg
D10061
dbp:legalStatus
Rx-only
dbp:legalUs
Rx-only
dbp:n
1712
dbp:o
1988
dbp:s
52
dbp:source
u
dbp:synonyms
KHK4827, AMG 827
dbp:target
dbr:Interleukin_17_receptor_A
dbp:tradename
Siliq, Kyntheum, Lumicef
dbp:type
mab
dbp:unii
6
dbp:verifiedfields
changed
dbp:verifiedrevid
459982905
dbp:watchedfields
changed
dbo:abstract
برودالوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج أمراض التهابية طورته آمجن. Brodalumab (v USA pod názvem Siliq, v Evropě Kyntheum) je lidská monoklonální protilátka určená k léčbě zánětlivých onemocnění.V únoru 2017 byl Brodalumab schválen FDA pro léčbu středně těžké až těžké (lupénky) u lidí, jejichž předchozí léčba selhala. Бродалумаб (brodalumab) — лекарственный препарат, моноклональное антитело. Одобрен для применения: США (февраль 2017 года). Le brodalumab est un anticorps monoclonal ciblant le récepteur A de l'interleukine 17 (IL-17RA). Il agit comme antagoniste des récepteurs à l'IL-17 comparativement aux autres inhibiteurs de l'IL-17, qui eux vont agir sur l'IL-17 et non sur son récepteur en la neutralisant. Il est aujourd'hui approuvé dans différentes juridictions dans le traitement du psoriasis modéré à sévère. Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases. In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.
dbp:dailymedid
Brodalumab
dbp:legalCa
Rx-only
dbp:legalEu
Rx-only
dbp:licenceUs
Brodalumab
dbp:mabType
mab
gold:hypernym
dbr:Antibody
prov:wasDerivedFrom
wikipedia-en:Brodalumab?oldid=1124010770&ns=0
dbo:wikiPageLength
8806
dbo:alternativeName
Siliq, Kyntheum, Lumicef
dbo:casNumber
1174395-19-7
dbo:drugbank
DB11776
dbo:fdaUniiCode
6ZA31Y954Z
dbo:kegg
D10061
foaf:isPrimaryTopicOf
wikipedia-en:Brodalumab
Subject Item
dbr:C6372H9840N1712O1988S52
dbo:wikiPageWikiLink
dbr:Brodalumab
dbo:wikiPageRedirects
dbr:Brodalumab
Subject Item
dbr:Amgen
dbo:wikiPageWikiLink
dbr:Brodalumab
Subject Item
dbr:Ixekizumab
dbo:wikiPageWikiLink
dbr:Brodalumab
Subject Item
dbr:AstraZeneca
dbo:wikiPageWikiLink
dbr:Brodalumab
Subject Item
dbr:ATC_code_L04
dbo:wikiPageWikiLink
dbr:Brodalumab
Subject Item
dbr:List_of_therapeutic_monoclonal_antibodies
dbo:wikiPageWikiLink
dbr:Brodalumab
Subject Item
n14:_Br
dbo:wikiPageWikiLink
dbr:Brodalumab
Subject Item
wikipedia-en:Brodalumab
foaf:primaryTopic
dbr:Brodalumab